RETINAL DISEASES
Iveric Bio, an Astellas Company is committed to developing innovative therapies that address unmet needs of patients suffering from the progressive symptoms of common and rare retinal diseases.
learn moreyour partner
in advancing
retina care
about us
Iveric Bio, an Astellas Company is an innovative biopharmaceutical company. Our focus is the discovery and development of treatments for retinal diseases with significant unmet medical needs, including geographic atrophy.
Our team of medical affairs professionals are leaders in the field. We are passionate about:- Generating accurate, compelling, and innovative scientific and medical data
- Sharing our emerging science to increase the understanding of retinal diseases and new treatments
- Partnering with the medical community to address the most challenging questions in retinal diseases
We aim to be a trusted source for scientific and clinical information and look forward to elevating retinal care together.
DISCOVER OUR LATEST ASSET:
MECHANISM OF ACTION VIDEOTake a moment to watch our informative mechanism of action (MOA) video, which depicts the inhibition of C5 in the complement pathway.
Publications
& Presentations
Iveric Bio, an Astellas Company is exploring new research frontiers in retinal disease. Learn more about our research on pipeline products.
learn more
Showcase Events
We are committed to supporting medical education, facilitating scientific exchange, and partnering with the medical community. Learn more at upcoming congresses, medical education events, and more.
learn moreOur Clinical Trials
Our management team and clinical advisors at Iveric Bio, an Astellas Company know the importance of vision for patients and practitioners. That is why we work to help eye care professionals connect their patients living with retinal diseases to our geographic atrophy trials and beyond.
EXPLORE OUR CLINICAL TRIALSOur Pipeline
With a diverse portfolio of therapeutic candidates at different stages of development, Iveric Bio, an Astellas Company is focused on bringing innovative treatments for retinal diseases to those who need them most.
EXPLORE OUR PIPELINE